Oxurion NV (GB:0G99)
LSE:0G99
0G99 Stock Chart & Stats
€0.27
€0.27(136397.69%)
At close: 4:00 PM EST
€0.27
€0.27(136397.69%)
Day’s Range― - ―
52-Week Range€0.27 - €0.27
Previous CloseN/A
Volume183.00
Average Volume (3M)0.00
Market Cap
€333.15K
Enterprise Value€11.08M
Total Cash (Recent Filing)€455.00K
Total Debt (Recent Filing)€11.33M
Price to Earnings (P/E)―
Beta-3.42
Next Earnings
Sep 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.09
Shares Outstanding111,049,580
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Oxurion NV News
0G99 FAQ
What was Oxurion NV’s price range in the past 12 months?
Oxurion NV lowest share price was €0.27 and its highest was €0.27 in the past 12 months.
What is Oxurion NV’s market cap?
Oxurion NV’s market cap is €333.15K.
When is Oxurion NV’s upcoming earnings report date?
Oxurion NV’s upcoming earnings report date is Sep 03, 2026 which is in 87 days.
How were Oxurion NV’s earnings last quarter?
Oxurion NV released its earnings results on Apr 03, 2026. The company reported -€0.041 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.041.
Is Oxurion NV overvalued?
According to Wall Street analysts Oxurion NV’s price is currently Overvalued.
Does Oxurion NV pay dividends?
Oxurion NV does not currently pay dividends.
What is Oxurion NV’s EPS estimate?
Oxurion NV’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oxurion NV have?
Oxurion NV has 111,049,580 shares outstanding.
What happened to Oxurion NV’s price movement after its last earnings report?
Oxurion NV reported an EPS of -€0.041 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Oxurion NV?
Currently, no hedge funds are holding shares in GB:0G99
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oxurion NV
Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist which is in Phase II clinical trials for the treatment of DME. It has collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.